RELMADA THERAPEUTICS, INC. Business Development
RELMADA THERAPEUTICS, INC. (RLMD) reported Business Development of $200.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessDevelopment · last filed 2026-08-06
- RELMADA THERAPEUTICS, INC. business development for the quarter ending 2026-06-30 was $0.00.
- RELMADA THERAPEUTICS, INC. business development for the quarter ending 2026-03-31 was $200.00M, a 0.00% change year-over-year.
- RELMADA THERAPEUTICS, INC. business development for the quarter ending 2025-12-31 was $0.00.
- RELMADA THERAPEUTICS, INC. business development for the quarter ending 2025-09-30 was $0.00.
- RELMADA THERAPEUTICS, INC. business development for fiscal 2025 was $200.00M.
| Period end | Business Development | Business Development 3 month | Business Development 6 month | Business Development 9 month | Business Development 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $200.00M 10-Q · filed 2026-08-06 | $200.00M derived: sum of 3 quarters · filed 2026-08-06 | $200.00M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $200.00M 10-Q · filed 2026-05-12 | $200.00M derived: sum of 2 quarters · filed 2026-05-12 | $200.00M derived: sum of 3 quarters · filed 2026-05-12 | $200.00M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $0.00 derived: sum of 2 quarters · filed 2026-03-19 | $0.00 derived: sum of 3 quarters · filed 2026-03-19 | $200.00M 10-K · filed 2026-03-19 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $200.00M 10-Q · filed 2025-11-13 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $200.00M 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $200.00M 10-Q · filed 2025-05-12 | ||||
| 2025-03-24 | $200.00M 10-Q · filed 2025-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |